Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online :

Original article / research
Table of Contents - Year : 2013 | Month : September | Volume : 7 | Issue : 9 | Page : 1959 - 1963

Experience with Biodegradable Polymer Coated Sirolimus-Eluting Coronary Stent System in “Real-Life” Percutaneous Coronary Intervention: 24-Month Data from the Manipal-S Registry 1959-1963

Ranjan Shetty, G. Vivek, Ashok Thakkar, Supriya Sunder Mishra, Vivek Joseph, Mithun Gopal Devraj, Anil Tumkur, Umesh Pai

Correspondence
Dr. Ranjan Shetty K.,
Associate Professor, Department of Cardiology, KMC, Manipal-576104, Karnataka, India.
Phone: +91 9243350978, E-mail: ranjanshettyk@yahoo.com

Introduction: Despite the undeniable clinical efficacy of drug-eluting stents with durable polymers, concerns regarding their long-term safety have been raised, especially in more complex subsets. The Manipal-S Registry was designed to evaluate the safety and effectiveness of the biodegradable polymer coated Supralimus® Sirolimus-Eluting Coronary Stent for the treatment of coronary artery disease, across a wide range of patients who are treated in real-life clinical practice.

Methods: All the consecutive 116 patients who underwent single-vessel or multiple vessel percutaneous coronary interventions with the use of Supralimus® sirolimus-eluting stents between September 2009 and December 2010, were included in this study. Patients were clinically followed-up at 1, 9, 12 and 24 months post-procedure. All clinical, procedural, and follow-up information were collected and analysed.

Results: In total 116 patients, 126 lesions were implanted with 144 stents which had an average stent length of 25.8±8.0 mm. The incidences of any major adverse cardiac and cerebral events at 1, 9, 12 and 24 months were 0, 5 (4.3%), 8 (6.9%), and 10 (8.6%) respectively.

Conclusion: These 24-month results clearly provide evidence for safety and effectiveness of the Supralimus® Sirolimus-eluting coronary stent system with the biodegradable polymer in real-life patients, even in those with acute myocardial infarctions.